Anlon Healthcare Limited reported a standalone net profit of ₹479.71 lakh for the quarter ended June 30, 2026, marking a 51% decline from ₹979.20 lakh in the preceding quarter (Q4FY26). However, the result represents a 35% increase compared to ₹354.69 lakh in the corresponding period of FY25. The company’s consolidated net profit rose 35% year-on-year to ₹828.14 lakh, driven by a significant expansion in the consolidated revenue base to ₹8756.27 lakh from ₹3329.72 lakh in Q1FY25.

The filing, submitted under Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was certified by Managing Director Punitkumar Rasadia. The results were published via newspaper advertisement in Financial Express on August 01, 2026, and filed with both BSE and NSE. No dividend was declared for the quarter.

Financial Performance Overview

While standalone pre-tax profits rose 18% year-on-year to ₹590.37 lakh from ₹500.41 lakh, the after-tax profit growth of 35% was more pronounced. This divergence suggests favorable tax adjustments or one-time credits not detailed in the extract. However, the broader context shows a sharp sequential decline from the previous quarter’s standalone PAT of ₹979.20 lakh, highlighting volatility in recent performance.

What the Numbers Show

The divergence between standalone and consolidated figures warrants attention. While standalone operations saw a slight dip in revenue year-on-year, consolidated income nearly tripled to ₹8756.27 lakh. This suggests that Anlon Healthcare may have integrated new subsidiaries or changed its consolidation methodology during FY27. Investors should monitor future disclosures for clarity on whether this consolidated base is sustainable or a one-off adjustment. Additionally, the flat EPS at ₹0.09 per share (basic) despite higher consolidated profits points to a significant increase in share capital—from ₹3985.15 lakh in Q1FY26 to ₹10630.30 lakh in Q1FY27—likely due to a face value reduction from ₹10 to ₹2 per share, which dilutes per-share metrics without changing overall equity value.

Anlon Healthcare reported its Q1 financial results, posting a net profit of 48M rupees, up from 35M rupees in the corresponding period last year. The improvement in profitability came alongside a notable expansion in operating margins, even as the company's top line saw a year-on-year decline.

Revenue Performance

Anlon Healthcare's Q1 revenue stood at 310M rupees, compared to 333M rupees in the same quarter last year, reflecting a year-on-year contraction in the top line. The revenue decline indicates softer demand or pricing conditions relative to the prior-year period.

Profitability and Margin Expansion

Despite the revenue dip, the company demonstrated meaningful improvement in its profitability metrics. The following table summarizes the key financial highlights for Q1 on a year-on-year basis:

EBITDA for the quarter came in at 75M rupees, rising from 62M rupees in the year-ago period. The EBITDA margin expanded to 24.08% from 18.73% YoY, indicating improved cost efficiency and operational leverage during the quarter.

Key Takeaways

• Net profit increased to 48M rupees from 35M rupees YoY
• Revenue declined to 310M rupees from 333M rupees YoY
• EBITDA improved to 75M rupees from 62M rupees YoY
• EBITDA margin expanded by approximately 535 basis points to 24.08% from 18.73% YoY

The Q1 results highlight Anlon Healthcare's ability to improve profitability and operating efficiency on a year-on-year basis, even as revenue faced headwinds. The significant margin expansion underscores stronger cost management relative to the prior-year quarter.